ZahiMitriMD

PubMed

• Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
  R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason ...> ;Nature Communications. 2023 Aug 7
• 5 citations
  Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
  R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason ...> ;Nature Communications. 2023 Jul 24
• 3 citations
  Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
  Shaun M Goodyear, Evthokia A Hobbs, Andy Kaempf, Thomas Kartika, Jessica Ribkoff, Brie Chun, Zahi I Mitri, West, M. T., Malinda T West> ;The Oncologist. 2023 Aug 3
• 3 citations
  Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study.
  Rajat Thawani, Lina Gao, Ajay Mohinani, Alina Tudorica, Xin Li, Zahi Mitri, Wei Huang> ;BMC Medical Imaging. 2022 Oct 20
• 1 citations
  Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.
  Claire E P Smith, Paul K Marcom, Zahi Mitri, Naomi Y Ko> ;Breast Cancer Research and Treatment. 2022 Nov 1
• 9 citations
  Impact of TP53 mutations in Triple Negative Breast Cancer.
  Zahi I Mitri, Nour Abuhadra, Shaun M Goodyear, Evthokia A Hobbs, Andy Kaempf, Alastair M Thompson, Stacy L Moulder> ;NPJ Precision Oncology. 2022 Sep 9
• 7 citations
  An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer.
  Brett E Johnson, Allison L Creason, Jayne M Stommel, Jamie M Keck, Swapnil Parmar, Courtney B Betts, Aurora Blucher, Christopher Boniface, Elmar Bucher, Erik Burlingam...> ;Cell Reports. Medicine. 2022 Feb 15
• 22 citations
  Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?
  Kerri M. Winters-Stone, Cassie Boisvert, Fuzhong Li, Karen S. Lyons, Tomasz M. Beer, Zahi Mitri, Gabrielle Meyers, Elizabeth Eckstrom, Kristin L. Campbell> ;Supportive Care in Cancer. 2021 Nov 6
• 8 citations
  Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
  Marilyne Labrie, Allen G. Li, Allison L. Creason, Courtney Betts, Jamie M. Keck, Brett Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, ...> ;NPJ Precision Oncology. 2021 Oct 19
• 13 citations
  A randomized-controlled trial comparing supervised aerobic training to resistance training followed by unsupervised exercise on physical functioning in older breast ca...
  Kerri M. Winters-Stone, Britta N. Torgrimson-Ojerio, Nathan F. Dieckmann, Sydnee Stoyles, Zahi Mitri, Shiuh-Wen Luoh> ;Journal of Geriatric Oncology. 2021 Aug 20
• 6 citations
  Study protocol for the Exercising Together© trial: a randomized, controlled trial of partnered exercise for couples coping with cancer
  Kerri M. Winters-Stone, Karen S. Lyons, Nathan F. Dieckmann, Christopher S. Lee, Zahi Mitri, Tomasz M. Beer> ;Trials. 2021 Aug 30
• 1 citations
  Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer
  Allen G. Li, Shaun M. Goodyear, Cristina Fuss, Zahi Mitri> ;JCO Precision Oncology. 2021 Jun 1
• 2 citations
  Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
  Luai Al Rabadi, Madeline Cook, Andy Kaempf, Megan M. Saraceni, Michael A. Savin, Zahi Mitri> ;BMC Cancer. 2021 Apr 6
• 13 citations
  Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics.
  Allen G. Li, Jamie M. Keck, Swapnil Parmar, Janice Patterson, Marilyne Labrie, Allison L. Creason, Brett Johnson, Molly Downey, George Thomas, Carol Beadling, Laura M....> ;NPJ Precision Oncology. 2021 Mar 26
• 26 citations
  Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors
  Matthew S. Dietz, Thomas L. Sutton, Brett S. Walker, Charles E. Gast, Luai Zarour, Sidharth K. Sengupta, John R. Swain, Jennifer Eng, Michael S. Parappilly, Kristen E....> ;Scientific Reports. 2021 Jul 1
• 21 citations
  CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
  Malinda West, Claire Elizabeth Powers Smith, Andy Kaempf, Tia C L Kohs, Ramin Amirsoltani, Jessica Ribkoff, Josh Lee Choung, Alison Palumbo, Zahi Mitri, Joseph J. Shatzel> ;European Journal of Haematology. 2021 May 1
• 2 citations
  Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer
  Swapnil Parmar, Jamie M. Keck, Ben Kong, Regan Look, Brett Johnson, Janice Patterson, Marilyne Labrie, Alexander R. Guimaraes, Christopher L. Corless, Carol Beadling, ...> ;JCO Precision Oncology. 2021 Jan 8
• 27 citations
  Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
  Madeline Cook, Luai Al Rabadi, Andy Kaempf, Megan M. Saraceni, Michael A. Savin, Zahi Mitri> ;The Oncologist. 2021 Feb 1
• 10 citations
  Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
  Allen G. Li, Stephen M. Schleicher, Fabrice Andre, Zahi Mitri> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2020 Mar 26
• 10 citations
  Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance.
  Marilyne Labrie, Yong Fang, Nicholas D. Kendsersky, Jun Li, Han Liang, Shannon N. Westin, Zahi Mitri, Gordon B. Mills> ;Advances in Experimental Medicine and Biology. 2019 Jan 1
• 26 citations
  Implementing a comprehensive translational oncology platform: from molecular testing to actionability
  Zahi Mitri, Swapnil Parmar, Brett Johnson, Annette Kolodzie, Jamie M. Keck, Max Morris, Alexander R. Guimaraes, Brooke Beckett, Uma Borate, Charles D. Lopez, Kathleen ...> ;Journal of Translational Medicine. 2018 Dec 14
• 25 citations
  TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
  Zahi Mitri, Rita Nanda, Kimberly L. Blackwell, Colleen M. Costelloe, Ilona Hood, Caimiao Wei, Abenaa M. Brewster, Nuhad K. Ibrahim, Kimberly B. Koenig, Gabriel N. Hort...> ;Clinical Cancer Research. 2016 Dec 1
• 10 citations
  BRCAPRO 6.0 model validation in male patients presenting for BRCA testing
  Zahi Mitri, Michelle Jackson, Carolyn Garby, Juhee Song, Sharon H. Giordano, Gabriel N. Hortobagyi, S. Shahrukh Hashmi, Banu Arun, Jennifer K. Litton> ;The Oncologist. 2015 Jun 1
• 51 citations
  A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
  Zahi Mitri, Cansu Karakas, Caimiao Wei, Brian Briones, Holly Simmons, Nuhad K. Ibrahim, Ricardo H. Alvarez, James L. Murray, Khandan Keyomarsi, Stacy L. Moulder> ;Investigational New Drugs. 2015 May 7
• 19 citations
  Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma
  Zahi Mitri, Momin T. Siddiqui, Fuad El Rassi, Jeannine T. Holden, Leonard T. Heffner, Amelia Langston, Edmund K. Waller, Elliott F. Winton, Morgan L. McLemore, Leon Be...> ;Leukemia & Lymphoma. 2014 May 2
• Join now to see all

Lectures

• A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer. 
  2019 ASCO Annual Meeting - 6/1/2019